Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents
Clinical trial NCT04954287 · COMPLETED
Trial details
- NCT number
- NCT04954287
- Sponsor
- CyanVac LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-06
- Primary completion
- 2023-06-10
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.